What Ocugen, Inc.’s OCU410ST milestone means for the race to treat inherited retinal blindness
Discover what Ocugen, Inc.’s OCU410ST milestone means for the future of inherited retinal blindness treatment and the race toward first approval.
Pharma & Biotech
Pharma & Biotech
Ocugen’s OCU410 shows early Phase 2 promise as a modifier gene therapy for geographic atrophy in dry AMD
Find out how Ocugen’s early Phase 2 results for OCU410 are shaping a new gene therapy approach for geographic atrophy in dry AMD.